Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients

Registry ID

EUCTR2008-005831-13

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

NERVIANO MEDICAL SCIENCES

Start date

2009-02-17

Last update

2026-08-16

Conditions

• Malignant Pleural Mesothelioma

Summary

To assess the antitumor activity in terms of TTP of PHA-848125AC as second-line treatment in pemetrexed-pretreated patients with MPM.

Locations

• , , Italy

Related clinical trials

• APG-2449 in Patients With Advanced Solid Tumors
• Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
• Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
• The IMmunotherapy Pleural 5-ALA PDT
• Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
• Hemithoracic Arc Radiotherapy Post Pleural Decortication

View on source registry